A new study has been published in Nature Communications, presenting the first comprehensive atlas of allele-specific DNA ...

"Our new fiscal 2025 guidance provides for limited further earnings contribution from China, and assumes a continuation of the macro trends we see today," said Ankur Dhingra, CFO of Illumina. "We will ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Illumina, Inc. (NASDAQ:ILMN) offers sequencing- and array-based solutions for genetic and genomic analysis. The one-month return of Illumina, Inc. (NASDAQ:ILMN) was -32.97%, and its shares lost 34 ...

The Genomics Core also offers quality assessment of most types of DNA and RNA, as well as Cell Line Authentication, Illumina BeadArray methylation and genotyping analysis. Samples can be submitted ...

In conclusion, ctDNA methylation in both tissue and plasma can effectively differentiate malignancy from benign disease and holds great potential as a biomarker for early lung cancer diagnosis.

Illumina's 5-base solution for methylation analysis and variant calling powers accuracy of genetic and epigenetic data. Currently in early access, Illumina's 5-base solution for methylation ...

Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform Built on ...

Illumina's 5-base solution for methylation analysis and variant calling ... established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research ...

and methylation, as well as a new multimodal data analysis platform Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale ...